LYMRIT 37-01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU-LILOTOMAB SATETRAXETAN, A NOVEL CD37-TARGETED ANTIBODY- RADIONUCLIDE-CONJUGATE IN RELAPSED NHL PATIENTS